ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

ODAC Votes Against Adria’s Chemoprotector, Okays Leustatin

July 3, 1992

In Brief: Responses To Control Grants Guidelines Pour Into NCI, Some From Grantsmen “Old Pros”

November 23, 1974

Obituary: Connie Curran, 67, C-Change Executive Director

November 21, 2014

White House Appoints Slamon To Cancer Panel; Brinker To Address Republican Convention.

July 28, 2000

NCI, NHGRI Fund Two More Components of TCGA Project.

October 27, 2006

MSK Withdraws Form Breast Cancer Nutrition Study Over Chemotherapy Issue; Program Still “Going Well”

June 21, 1985